Alopecia prevention during chemotherapy: from the benchmark to real clinical practice. A prospective study
Authors:
- Marina A. LyadovaMLMarina A. Lyadova
- Tatiana A. NersesovaTNTatiana A. Nersesova
- Anastasia A. ZhuravlevaAZAnastasia A. Zhuravleva
- Denis S. FedorinovDFDenis S. Fedorinov
- Anna A. DudnikADAnna A. Dudnik
- Elena A. DenisovaEDElena A. Denisova
- Margarita V. NosovaMNMargarita V. Nosova
- Olesya A. PardabekovaOPOlesya A. Pardabekova
- Kristina N. LisitsynaKLKristina N. Lisitsyna
- Veronika M. TuleikoVTVeronika M. Tuleiko
- Olesya A. BikmurzinaOBOlesya A. Bikmurzina
Open Access
- 21 February 2024
- journal article
- research article
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 25 (4) , 498-503
Abstract
Background. Alopecia is one of the main side effects of anticancer chemotherapy and has a significant impact on patients’ appearance, quality of life, social adaptation and mental health of cancer patients. Estimated number of new cancer diagnosis increases annually alongside with the proportion of patients receiving chemotherapy. That means an annual increase in the global burden of chemo-induced alopecia and associated negative consequences. The development of various methods for the prevention of alopecia in cancer patients has continued for decades. However, convincing data have been obtained only for the scalp hypothermia method. In this point, the Paxman company’s cooling systems (UK) – the Orbis and Orbis II devices – have been most widely studied. Despite the fact that Orbis devices were approved in Russia more than 10 years ago, since then just a small amount of real clinical practice has been accumulated and questions regarding the effectiveness of scalp hypothermia in patients with variable cancers still remain open. Aim. Analysis of local clinical practice with scalp hypothermia via the Orbis II device for the prevention of alopecia in patients receiving various chemotherapy regimens. Materials and methods. An open, prospective, single-center study included patients with various cancer types who were indicated for chemotherapy. Orbis II device was used for prophylactic hypothermia. The severity of alopecia was assessed according to the CTCAE version 5.0 at baseline and during anticancer therapy. Results. From June 2022 to May 2023, scalp cooling procedures were performed in 51 patients, of them 78% of all procedures were performed in female cancers: breast tumors – 109 (52.2%) procedures, ovarian cancer– 33 (15.8%), and cervix cancer – 22 (10.5%). The effectiveness of scalp hypothermia in preventing of severe alopecia was 73%. Conclusion. Scalp cooling can be considered as an effective method for the prevention of chemotherapy induced alopecia. Further studies are needed to assess larger patient populations to identify favorable and negative factors that affect potency of the hypothermia.Keywords
This publication has 24 references indexed in Scilit:
- A Clinical and Biological Guide for Understanding Chemotherapy-Induced Alopecia and Its PreventionThe Oncologist, 2017
- Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast CancerJAMA, 2017
- Results of scalp cooling during anthracycline containing chemotherapy depend on scalp skin temperatureThe Breast, 2016
- Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patientsPsycho-Oncology, 2014
- Pathobiology of chemotherapy-induced hair lossThe Lancet Oncology, 2013
- Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients - Results of the Dutch Scalp Cooling RegistryActa Oncologica, 2012
- Protection Against Chemotherapy-Induced AlopeciaPharmaceutical Research, 2006
- A multicentre study to determine the efficacy and patient acceptability of the Paxman Scalp Cooler to prevent hair loss in patients receiving chemotherapyEuropean Journal of Oncology Nursing, 2004
- A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopeciaAnti-Cancer Drugs, 1999
- Minoxidil (Mx) as a prophylaxis of doxorubicin – induced alopeciaAnnals of Oncology, 1994